Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Lantus (insulin glargine) and Ozempic (semaglutide) are both medications used to manage diabetes, but they belong to different medication classes and have distinct uses. Lantus is a long-acting insulin that helps control blood sugar levels in both Type 1 and Type 2 diabetes by providing a steady release of insulin throughout the day. It's typically injected once daily. On the other hand, Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist that not only helps manage Type 2 diabetes but also lowers the risk of heart attack, stroke, and death in adults with Type 2 diabetes and heart disease. It's injected once a week. While Lantus is available as a vial and prefilled pen, Ozempic comes only as a prefilled pen. Common side effects of Lantus include redness at the injection site and upper respiratory infections, whereas Ozempic often causes nausea, vomiting, and diarrhea. Both medications can interact with alcohol, but Ozempic also has specific warnings about thyroid cancer and pancreatitis. Lantus is available as a generic medication, while Ozempic is not.
Lantus (insulin glargine)
Ozempic (semaglutide)
Lantus (insulin glargine)
Ozempic (semaglutide)
Summary of Lantus vs. Ozempic
Summary for Insulin
Prescription only
Lantus (insulin glargine) is a type of long-acting insulin. It's used to help manage blood sugar levels in people with Type 1 diabetes or Type 2 diabetes. Lantus (insulin glargine) is injected under the skin once daily. Your dose will depend on a few things, such as the type of diabetes you have and your blood sugar levels. This medication comes in a vial (Lantus) as well as in a prefilled insulin pen (Lantus Solostar). Some side effects include upper respiratory tract infections. It can also cause redness and swelling at the injection site.
Summary for GLP-1 agonist
Prescription only
Ozempic (semaglutide) is a prescription injection used with diet and exercise to help manage Type 2 diabetes in adults. It's also FDA approved to lower the risk of heart attack, stroke, and heart-related death in those with Type 2 diabetes and heart disease. In addition, it can reduce the risk of worsening kidney problems in people with Type 2 diabetes and chronic kidney disease (CKD). Ozempic (semaglutide) is a GLP-1 agonist that's injected under the skin once a week. Common side effects include nausea, vomiting, and diarrhea.